Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

191

Participants

Timeline

Start Date

April 16, 2010

Primary Completion Date

August 12, 2014

Study Completion Date

July 19, 2017

Conditions

Ovarian CarcinomaFallopian Tube CancerPeritoneal CancerBreast Carcinoma

Interventions

DRUG

Alisertib

Alisertib tablets

DRUG

Paclitaxel

Paclitaxel intravenous infusion

Trial Locations (4)

The Bronx

Philadelphia

Houston

Seattle